Skip to Main Content

Paper Details

Impact of Therapy on Genomics and Transcriptomics in High-Risk Prostate Cancer Treated with Neoadjuvant Docetaxel and Androgen Deprivation Therapy.
Clin Cancer Res
59
2017
-, 163 genes, AR, AR-V7, Androgen, Docetaxel, ERG, FOXA1, High-Risk Prostate Cancer, PTEN, PTEN deletion, SPOP, TMPRSS2, TP53, androgen, docetaxel, formalin, germline, metastatic prostate cancer, paraffin, patients, plasticity genes, prostate cancer, residual cancer, tumor, tumors
Author NameAffiliation
Himisha BeltranWeill Medical College of Cornell University
Himisha BeltranWeill Medical College of Cornell University
Alexander W WyattUniversity of British Columbia
Matti AnnalaInstitute of Biosciences and Medical Technology, University of Tampere
Michael SigourosWeill Medical College of Cornell University
Fan MoUniversity of British Columbia
Ladan FazliUniversity of British Columbia
Colin C CollinsUniversity of British Columbia
Michael J Morris
Mary-Ellen TaplinWeill Medical College of Cornell University
Andrea SbonerInstitute for Computational Biomedicine, Weill Medical College of Cornell University
Andrea SbonerInstitute for Computational Biomedicine, Weill Medical College of Cornell University
Andrea SbonerMemorial Sloan Kettering Cancer Center
Andrea SbonerMemorial Sloan Kettering Cancer Center
Martin E GleaveUniversity of British Columbia
  • 1 - 15

Datasets

Release 1.2